M. Kulyk & Associates LLC Sells 19,203 Shares of Zoetis Inc. (NYSE:ZTS)

M. Kulyk & Associates LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 52.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,306 shares of the company's stock after selling 19,203 shares during the quarter. M. Kulyk & Associates LLC's holdings in Zoetis were worth $2,849,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ZTS. Navigoe LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $30,000. Cornerstone Planning Group LLC increased its position in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis during the 4th quarter worth approximately $44,000. Finally, Sound Income Strategies LLC boosted its stake in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 2.6%

Shares of ZTS stock traded up $3.82 during trading on Tuesday, reaching $151.19. The company's stock had a trading volume of 4,560,583 shares, compared to its average volume of 2,636,401. The company has a market cap of $67.31 billion, a price-to-earnings ratio of 27.14, a price-to-earnings-growth ratio of 2.44 and a beta of 0.91. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The business has a fifty day moving average price of $160.77 and a 200-day moving average price of $161.42. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.32%. Zoetis's dividend payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ZTS shares. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler upped their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $204.63.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.